SWK Holdings Monetizes Royalty Portfolio with Key Transactions

SWK Holdings Corporation, a specialty finance company focused on life sciences, announced significant monetization of its royalty portfolio. This move comprises two pivotal transactions.

First, ANI Pharmaceuticals, Inc. executed its buyout option for the Iluvien royalty, resulting in a $17.3 million payment to SWK. Additionally, SWK struck a deal with Soleus Capital to sell most of its remaining royalty portfolio for approximately $34.0 million in cash. This Soleus transaction is expected to finalize in about two weeks, pending standard closing conditions.

Together, these transactions amount to roughly $51.3 million, reflecting a $1.0 million gain over the portfolio’s book value as of December 31, 2024. SWK anticipates announcing a shareholder dividend upon the Soleus deal closure.